PathToScale: The PERSIST Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

9900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-01

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PathToScale: An Implementation Evaluation

NCT06319105

Oral Pre-exposure Prophylaxis (PrEP) Long-acting Injectable Cabotegravir for PrEP

RECRUITING

Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

NCT06133686

HIV

NOT_YET_RECRUITING PHASE3

Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi

NCT05510973

Opportunistic Infections, HIV-Related Cryptococcal Infections AIDS With Tuberculosis +2 more

UNKNOWN NA

Examining HIV Treatment Adherence During Early Disease

NCT02419066

Medication Adherence HIV

COMPLETED

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples

NCT00557245

HIV-1 Infections HIV Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will test a package of implementation strategies to support continuation on pre-exposure prophylaxis (PrEP), with a particular focus on long-acting injectable cabotegravir (CAB LA). The study will prioritize impacts on PrEP continuation at 5-months and will secondarily consider alternate continuation endpoints, acceptability, feasibility, appropriateness and fidelity of implementation strategies among CAB LA users and providers. The study will use an efficient hybrid type 3 pragmatic cluster randomization. Clusters are defined as delivery sites, including primary health centers (PHCs) and private clinics serving the broader population and drop-in centers/community-based organizations providing CAB LA to prioritized populations including female sex workers, clients, men who have sex with men and transgender persons.

Clusters will be randomized to receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation vs. an enhanced bundle of clinical support and provider-focused implementation strategies to promote sustained PrEP use. Variable-constrained randomization will be applied to balance allocation by facility type (drop-in centre for female sex workers, drop-in centre for men who have sex with men, primary health clinic, hospital, private), and overall clinic/PrEP volume.

PrEP users will be passively enrolled into the cluster randomized trial and a subset actively enrolled for participation in the targeted research activities. De-identified programmatic data will be utilized from OCR technology called ScanForm, which was developed by QED PrEP to identify the number and demographic characteristics (gender, age, indication for PrEP) of oral and CAB LA PrEP users initiating PrEP modalities by site, switching from oral to CAB LA PrEP (and vice versa), and continuation rates.

Outcomes of PrEP persistence will be followed for at least 5 months. Follow-up will begin at the time of injectable or oral PrEP initiation. With a 6-month passive enrollment period across sites and at least 5 months of follow-up of all clients initiating oral or injectable PrEP, this will result in 5-11 months of follow-up data per facility.

In addition to the utilization of programmatic data documenting PrEP continuation overall, and by PrEP modality (oral vs. CAB LA), a number of discrete research activities will be undertaken to evaluate the secondary objectives of the cluster randomized trial. These include: (1) serial cross-sectional surveys with PrEP clients; (2) In-depth qualitative interviews with PrEP clients; (3) Fidelity assessments of implementation strategies.

During a quantitative analysis, the primary endpoint (continuation of CAB LA at 5 months) will be compared as an intention-to-treat analysis across clusters of clinics implementing the standard of care continuation support for CAB LA vs. clinics implementing the enhanced continuation support package. The primary analysis will be an unpaired t-test to compare cluster-level proportions between the two study arms for each of the primary endpoints. We will further apply log-binomial regression to evaluate the difference in the study arms adjusting for stratification variables and individual-level characteristics that may be associated with the outcome. Similar analytical approaches will be followed for secondary endpoints.

For qualitative analysis, clients across priority populations and delivery channels will be identified for in-depth interviews (IDIs). We will enroll 100 clients to complete an IDI. With a sample size of around n=100, we promote feasibility and representation. Notably as this is not an ethnographic study, we will not seek to reach saturation in any of the groups, but rather to ensure that a diverse set of perspectives and experiences are represented which will allow for greater understanding of consistencies and variations in CAB LA implementation across populations and delivery channels.

Across the IDIs, we will audio record transcripts and use rapid qualitative analysis methods to efficiently translate research findings. Rapid analysis will include the write-up of detailed notes within 24 hours of the interview by the note- taker, and generation of an analytic memo utilizing structured templates within 2-business days of the interview by the moderator, listening to the audio recording where necessary for clarification; the note taker and moderator will then jointly review the memo and reach consensus. Matrices will be completed for each interview and memos detailing emerging themes created, allowing for within and across participant comparisons. A thematic analysis utilizing the memos and field notes will be applied deductively using CFIR domains and valence rating, with inductive themes added; audio recordings will be transcribed for further cross-reference and quotes. This approach, common in implementation science, will allow for more rapid identification and application of findings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Pre-exposure Prophylaxis (PrEP) Long-acting Injectable Cabotegravir for PrEP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a parallel design with all intervention facilities implementing the enhanced continuation package of strategies or standard of care (SoC) simultaneously.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care (SoC)

Receive the standard of care (SoC) per Ministry of Health guidelines for PrEP continuation.

Group Type ACTIVE_COMPARATOR

Standard of Care (SoC)

Intervention Type BEHAVIORAL

Participants will receive the standard of care per national guidelines of PrEP counseling, national program quality improvement activities, and follow up text messages and phone calls after missed visit.

Enhanced continuation support package

Enhanced bundle of clinical support and provider focused intervention package to promote sustained PrEP use.

Group Type ACTIVE_COMPARATOR

Standard of Care (SoC)

Intervention Type BEHAVIORAL

Participants will receive the standard of care per national guidelines of PrEP counseling, national program quality improvement activities, and follow up text messages and phone calls after missed visit.

Enhanced continuation support package

Intervention Type BEHAVIORAL

Participants will receive the SoC and bundle of enhanced PrEP continuation support strategies with the following provider, client and structural components:

1. improving provider-client empathy and communication
2. expert client/ peer 'Dolo wa PrEP'
3. early openings of clinics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care (SoC)

Participants will receive the standard of care per national guidelines of PrEP counseling, national program quality improvement activities, and follow up text messages and phone calls after missed visit.

Intervention Type BEHAVIORAL

Enhanced continuation support package

Participants will receive the SoC and bundle of enhanced PrEP continuation support strategies with the following provider, client and structural components:

1. improving provider-client empathy and communication
2. expert client/ peer 'Dolo wa PrEP'
3. early openings of clinics

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Individuals who are 15+ years old AND either

1. Female sex workers (FSW) OR
2. Men who have sex with men (MSM) OR
3. Transgender individuals (TG) OR
4. Women and adolescent girls and young women (AGYW) presenting at STI services and/or family planning and/or HIV testing services OR
5. Breastfeeding women (BFW) OR
6. Male partners of female sex workers and/or Men at high risk for HIV and/or men presenting with a syndromic or lab-confirmed sexually transmitted infections. All individuals initiated on long-acting injectable cabotegravir for pre-exposure prophylaxis 15 years or above will be included in the passively enrolled sample.

Exclusion Criteria

Those living with HIV-1 or evidence of possible acute HIV infection OR Those with a prior Hepatitis B diagnosis OR Those with a known history of severe side effects to Cabotegravir Long Acting OR Those unwilling or unable to return for 3-monthly HIV testing or 2-monthly counseling and safety monitoring visits OR Clients currently on multi-drug resistance tuberculosis (MDR-TB) medications OR Clients currently taking post-exposure prophylaxis.

Minimum Eligible Age

15 Years

Maximum Eligible Age

110 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes